Loretta J. Nastoupil, MD, on Phase III Study on Mosunetuzumab, Rituximab, and Lenalidomide for Follicular Lymphoma

Posted: Wednesday, August 24, 2022

Loretta J. Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, discusses the CELESTIMO trial, which will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide compared with rituximab in combination with lenalidomide in patients with relapsed or refractory follicular lymphoma who have received at least one line of prior systemic therapy. The trial is still recruiting participants at 150 sites in 16 countries.